Allogene Therapeutics (ALLO) Income towards Parent Company: 2018-2024
Historic Income towards Parent Company for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to -$257.6 million.
- Allogene Therapeutics' Income towards Parent Company rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
- As of FY2024, Allogene Therapeutics' Income towards Parent Company stood at -$257.6 million, which was up 21.29% from -$327.3 million recorded in FY2023.
- Allogene Therapeutics' 5-year Income towards Parent Company high stood at -$250.2 million for FY2020, and its period low was -$331.0 million during FY2022.
- Over the past 3 years, Allogene Therapeutics' median Income towards Parent Company value was -$327.3 million (recorded in 2023), while the average stood at -$305.3 million.
- As far as peak fluctuations go, Allogene Therapeutics' Income towards Parent Company tumbled by 35.55% in 2020, and later climbed by 21.29% in 2024.
- Allogene Therapeutics' Income towards Parent Company (Yearly) stood at -$250.2 million in 2020, then dropped by 2.71% to -$257.0 million in 2021, then fell by 28.78% to -$331.0 million in 2022, then grew by 1.12% to -$327.3 million in 2023, then climbed by 21.29% to -$257.6 million in 2024.